Abstract:The targeted delivery of anti-tumor drugs to diseased sites is significant in cancer therapy. Herein, a novel redox-responsive 5-fluorouracil (5-FU) prodrug delivery system based on mesoporous silica nanoparticles was proposed, in which polyethyleneimine (PEI, a bulky gatekeeper) and (3-aminopropyl) triethoxysilane-functionalized MCM41 were conjugated to an identical 3,3-diselanediyldipropionic acid linker via a condensation reaction between the amino group and carboxyl functional group. The chemotherapeutic reagent 5-FU was filled into the pores of Se-MCM41 nanocarriers as a model drug. The nanoparticles of PEI-Se-MCM41@5-FU exhibited a uniform and spherical morphology of approximately 175 nm. Under high concentrations of reactive oxygen species or glutathione (GSH) environments, such as the tumor microenvironment, 5-FU was rapidly released from the PEI-Se-MCM41 nanocarrier owing to its high sensitivity to both oxidizing and reducing agents. The release performance clearly verified the feasibility of PEI-Se-MCM41@5-FU nanoparticles for H 2 O 2 /GSH-triggered 5-FU release, particularly under GSH conditions. Additionally, the cytotoxic effects of PEI-Se-MCM41 nanoparticles findings indicating that there was no significant cytotoxicity against CT-26 colon cancer cells after 24 h incubation. However, PEI-Se-MCM41@5-FU nanoparticles exhibited a pronounced inhibitory effect on CT-26 cells at a concentration of 150 μg mL −1 . Furthermore, the intracellular drug delivery performance of nanocarriers were evaluated using confocal laser scanning microscopy (CLSM), which disclosed that the PEI-Se-MCM41@RhB was successfully endocytosed into the CT-26 cells and released the loaded 5-FU. The conclusion was further proved by FACS analysis, which indicated that PEI-Se-MCM41@RhB was more easily uptaken into the CT-26 cells than free RhB. The findings of in vivo and in vitro studies suggest that PEI-Se-MCM41@5-FU holds great potential for effective tumor therapy.

RGD Peptide-Conjugated Selenium Nanoparticles: Antiangiogenesis by Suppressing VEGF-VEGFR2-ERK/AKT Pathway.

RGD Peptide-Conjugated Selenium Nanocomposite Inhibits Human Glioma Growth by Triggering Mitochondrial Dysfunction and ROS-Dependent MAPKs Activation

The Rational Design of Nami-A-Loaded Mesoporous Silica Nanoparticles As Antiangiogenic Nanosystems

The Effects of Luminescent Ruthenium(ii) Polypyridyl Functionalized Selenium Nanoparticles on Bfgf-Induced Angiogenesis and AKT/ERK Signaling

Rational Design of Cancer-Targeted Selenadiazole Derivative As Efficient Radiosensitizer for Precise Cancer Therapy

GE11 Peptide Conjugated Selenium Nanoparticles for EGFR Targeted Oridonin Delivery to Achieve Enhanced Anticancer Efficacy by Inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK Pathways

Targeted Anti-Cancer Therapy: Co-Delivery of VEGF siRNA and Phenethyl isothiocyanate (PEITC) via cRGD-Modified Lipid Nanoparticles for Enhanced Anti-Angiogenic Efficacy

The use of pH-sensitive functional selenium nanoparticles shows enhanced in vivo VEGF-siRNA silencing and fluorescence imaging.

GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways.

Selective Cellular Uptake and Induction of Apoptosis of Cancer-Targeted Selenium Nanoparticles.

Hyaluronic Acid-RGD Peptide Conjugated Mesoporous Silica-coated Gold Nanorods for Cancer Dual-targeted Chemo-photothermal Therapy

Engineering siRNA-loaded and RGDfC-targeted selenium nanoparticles for highly efficient silencing of DCBLD2 gene for colorectal cancer treatment

Enhanced Nanodrug Delivery to Solid Tumors Based on a Tumor Vasculature-Targeted Strategy

Red Fluorescent ZnO Nanoparticle Grafted with Polyglycerol and Conjugated RGD Peptide As Drug Delivery Vehicles for Efficient Target Cancer Therapy.

Tumor-penetrating Peptide Conjugated and Doxorubicin Loaded T1-T2 Dual Mode MRI Contrast Agents Nanoparticles for Tumor Theranostics

ROS-responsive Selenium-Containing Polyphosphoester Nanogels for Activated Anticancer Drug Release

ROS/GSH dual-responsive selenium-containing mesoporous silica nanoparticles for drug delivery

Crgd Mediated Redox and Ph Dual Responsive Poly(amidoamine) Dendrimer-Poly(ethylene Glycol) Conjugates for Efficiently Intracellular Antitumor Drug Delivery.

Dual function of RGD-modified VEGI-192 for breast cancer treatment.

Crgd-Functionalized Mpeg-Plga-Pll Nanoparticles for Imaging and Therapy of Breast Cancer

Rational Design of Cancer-Targeted Benzoselenadiazole by Rgd Peptide Functionalization for Cancer Theranostics